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.2012.10.Abstract Background: Mirtazapine is an antidepressant drug that blocks central 5-HT2 receptors
with anxiolytic and sleep-promoting effects and theoretically can be used as a premedication.
Methods: Sixty ASA I-II patients aged 25–50 yr were randomly allocated according to the premed-
ication received 2 h before induction of anesthesia into two equal groups: group M patients received
mirtazapine 30 mg tablet mixed with 20 ml of water and group P patients received 20 ml of plain
water. Anxiety level was measured by visual analogue scale (VAS) and bispectral index (BIS) elec-
trodes were connected before induction of anesthesia. Intravenous (i.v) infusion of propofol 1% at a
rate of 300 ml h1 was started to induce hypnosis till a target BIS value of 45 (BIS45) is reached,
and then endotracheal intubation is performed after fentanyl and cis-atracuruim being adminis-
tered. Propofol dose requirements to achieve loss of response to verbal contact (RVC), loss of eye-
lash reﬂex (ELR), and a target BIS45 were recorded. Anesthesia was maintained with sevoﬂurane
titrated to BIS value of 40–50 and oxygen/air mixture. Recovery time was recorded. In postanaes-
thesia care unit (PACU), VAS for pain and Ramsay sedation score were recorded. Patients wereical Complex, PO Box 946,
966 567320660; fax: +966
om
ptian Society of Anesthesiol-
g by Elsevier
nesthesiologists. Production and hosting by Elsevier B.V.
004
Open access under CC BY-NC-ND license.
144 E.E. Mansourdischarged from PACU when two consecutive Aldrete scores of 9 or 10 are obtained, and time of
PACU stay was recorded.
Results: Preoperative anxiety by VAS and propofol doses required achieving loss of RVC and
ELR, and target BIS45 were signiﬁcantly lower in mirtazapine group. The two groups were com-
parable with regard to recovery and PACU stay times as well as postoperative pain and anxiety.
Conclusion: Mirtazapine 30 mg oral tablets can be used as a premedication as it reduces preoper-
ative anxiety and hypnotic dose requirements of propofol, and does not prolong recovery time.
ª 2012 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
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Previous publications have investigated the clinical effect of
different drugs used for premedication namely, midazolam,
hydroxyzine, clonidine, nimodipine, and melatonin on
induction and maintenance doses of propofol using different
endpoints [1–5]. Mirtazapine is a novel, dual-acting antidepres-
sant that possesses a potent central a2-adrenoceptor blocking
effect as well as 5-HT2 and 5-HT3 receptors antagonism. The
antidepressant effect is due to enhancement of serotonergic
and noradrenergic systems in the CNS mediated via blocking
presynaptic a2-adrenoceptors with subsequent enhancement
of postsynaptic availability of Norepinephrine [6]. In addition,
mirtazapine antagonizes a2-adrenoceptors in the serotonergic
nerve terminals, therefore, increasing serotonin release.
Mirtazapine enhances serotonergic transmission only at
5-HTA1 receptors. It also blocks 5-HT2 and 5-HT3 receptors
[7] with subsequent anxiolytic and sleep-promoting effects
mediated via blocking central 5-HT2 receptors [8,9]. Theoreti-
cally, mirtazapine can be used as a premedication to provide
preoperative anxiolysis and may reduce the induction dose of
propofol via sleep-promoting effect.
The goal of the current study is to test the hypothesis that
mirtazapine premedication can reduce preoperative anxiety,
and induction dose of propofol.2. Methods
This study was conducted in the period from January 2012 to
April 2012 at King Fahd Military Medical Complex (Dhahran,
Eastern Province, Saudi Arabia) following approval of the Eth-
ics and Research Committee. Sixty adult patients aged 25–
50 years of both sexes, with American Society of Anesthesiolo-
gists (ASA) physical status I or II, and scheduled for a variety
of elective surgical procedures were included in the study after
getting their signed informed written consent. Patients with
known hypersensitivity to mirtazapine, taking any other anti-
depressant drug, receiving monoamine oxidase inhibitor, cur-
rent prescription of benzodiazepines, renal disease, hepatic
disease, or lactating females were excluded from the study.
Patients were randomly allocated (randomization was per-
formed with the help of a computer-generated random number
sequence program) to receive either mirtazapine 30 mg chew-
ing tablet which was ground and mixed with 20 ml of water
in an opaque cup (Mirtazapine or M group, n= 20) or
20 ml of plain water in an opaque cup (Placebo or P group,
n= 20) 2 h (hrs) preoperatively by an independent ward nurse
who was blinded to the study. On receiving the patient in the
operating room (OR) and before connecting the monitors,the anxiety level was measured in all patients using visual ana-
logue scale (VAS) for subjective feeling of anxiety by the
attending anesthesiologist who was also blinded to the premed-
ication. VAS for subjective feeling of anxiety consists of a
10 cm line anchored at one end by a label such as ‘‘not anx-
ious’’ and at the other end by a label such as ‘‘anxious as
can be’’. The use of VAS was explained to each patient in
the preoperative visit. Standard monitors were used including
electrocardiography (ECG), non-invasive arterial blood pres-
sure monitor (NIBP), pulse oximetry (SpO2), and capnogra-
phy. The baseline heart rate (HR) and both systolic and
diastolic arterial blood pressures (SBP & DBP) were recorded.
Bispectral index (BIS) monitor (BIS version 3.2, Aspect
Medical Systems Inc., Newton, MA, USA) was connected to
all patients prior to induction of anesthesia. After preoxygen-
ation, anesthesia was induced by continuous intravenous (i.v)
infusion of propofol solution 1% mixed with 2 ml of ligno-
caine 1% at a rate of 300 ml h1 by a syringe pump till a target
BIS value of 45 is reached (BIS45), then, propofol infusion was
stopped. The total dose of propofol required achieving loss of
response to verbal communication (RVC), loss of eyelash re-
ﬂex (ELR), and a target BIS45 as well as the time needed for
propofol achieving a target BIS45 (PropofolBIS45) were re-
corded in all patients. Also, the HR, SBP, and DBP at BIS45
were recorded by the same attending anesthesiologist. After
that, 2 lg kg1 of fentanyl was given and 0.15 mg kg1 of
cis-atracuruim to facilitate intubation of the trachea. Anesthe-
sia was maintained with sevoﬂurane and oxygen/air mixture
(FiO2 = 0.6). Sevoﬂurane concentration was titrated to main-
tain BIS value between 40 and 50 (BIS40–50) and was turned off
at the end of surgery. Recovery time was deﬁned as the time
from discontinuation of sevoﬂurane till the patient can grasp
his or her hand on command. To reverse residual neuromuscu-
lar block, 50 lg kg1 of i.v neostigmine and 20 lg kg1 of atro-
pine were given.
In post-anesthesia care unit (PACU), VAS for pain and
Ramsay sedation score were recorded by the PACU nurse
who was also blinded to the study. When two consecutive
Aldrete scores [10] of 9 or 10 are obtained, patients are dis-
charged from the PACU and time of PACU stay is recorded
in all patients.
In a preliminary unpublished pilot study conducted on 50
unpremedicated patients who received i.v infusion of propofol
1% at a rate of 300 ml h1 to reach our endpoint of a target
BIS45, we found that propofol dose requirement to reach
BIS45 was 141 ± 28. Based on that, the group size necessary
to detect a clinically relevant difference of 25% in propofol
dose requirements to reach BIS45 was estimated to be 27 pa-
tients per group to give a power of 0.8 at a level of P= 0.05
(a error = 0.05; b error = 0.1). To overcome potential drop-
Table 3 Hemodynamics before and after propofol induction
at BIS45.
Group M (n= 30) Group P (n= 30) P value
HR
Baseline 77 (60–93) 79 (64–94) 0.263
At BIS45 72.5 (56–93) 76 (60–89) 0.510
SBP
Baseline 116 (105–143) 121 (108–152) 0.184
At BIS45 110 (100 – 133) 115.5 (105–136) 0.214
DBP
Baseline 73 (60–94) 79 (62–92) 0.469
At BIS45 72 (58–83) 71.5 (60–87) 0.663
Group M=mirtazapine group; Group P = placebo group;
HR= heart rate; SBP = systolic blood pressure; DBP= diastolic
blood pressure; n= number.
Data are expressed median (range).
Table 4 Postoperative pain and anxiety scores.
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were preoperative anxiety level, induction time by propofol
infusion, hemodynamics, recovery and PACU stay times,
and postoperative pain and anxiety scores.
Data were presented as mean ± SD, median (range), or
number (percentage) as appropriate. Numerical demographic
data, propofol dose requirements, propofol induction time,
hemodynamics, durations of anesthesia and surgery, and
recovery and PACU stay times were compared using unpaired
student’s t-test, while categorical data were compared using
Chi-square (v2) or Fischer’s exact test as appropriate. Preoper-
ative anxiety score (VAS), and postoperative pain (VAS) and
sedation (RSS) scores were compared using Mann–Whitney
U-test. A P-value <0.05 was considered as statistically signif-
icant. Statistical software package (Graph Pad In Stat ver-
sion 3.00 for Windows, Graph Pad Software Inc., San
Diego, California, USA) was used for data analysis.
3. Results
In this randomized, placebo controlled, double blinded study,
sixty patients were randomly allocated into to two groups:Table 1 Demographic data, and duration of surgery and
anesthesia.
Group M
(n= 30)
Group P
(n= 30)
P value
Patient demographics
Age (years) 43.4 ± 6.7 44.1 ± 8.2 0.719
Gender (male/female) 18 (60)/12 (40) 21(70)/9 (30) 0.589
Weight (kg) 83.6 ± 18.1 81.4 ± 18.7 0.645
Duration of surgery (min) 44.6 ± 17.3 43.8 ± 19.2 0.866
Duration of anesthesia (min) 67.3 ± 18.2 72.1 ± 20.4 0.340
Group M=mirtazapine group; Group D= midazolam group;
Group P = placebo group; n= number; min = minutes.
Data are expressed as mean ± SD, or number (percentage).
Table 2 Effect of mirtazapine on preoperative anxiety,
propofol requirements, propofol induction time, recovery time,
and PACU stay.
Group M
(n= 30)
Group P
(n= 30)
P value
Preoperative anxiety (VAS) 3 (1–5)** 8 (5–9) <0.001
Propofol requirements (mg)
Loss of RVC 104 ± 15* 118 ± 19 0.003
Loss of ELR 107 ± 16* 123 ± 22 0.002
BIS45 112 ± 19
** 139 ± 25 <0.001
PropofolBIS45 (min) 2.1 ± 0.26
* 2.5 ± 0.30 <0.001
Recovery time (min) 10.3 ± 2.6 10.8 ± 2.9 0.485
PACU stay (min) 31.8 ± 6.8 30.1 ± 6.5 0.326
Group M=mirtazapine group; Group P = placebo group;
VAS = visual analogue scale; RVC= response to verbal contact;
ELR= eyelash reﬂex; PropofolBIS45 = time needed for propofol
achieving BIS45; n= number; min = minutes.
Data are expressed as mean ± SD, or median (range).
* P< 0.05.
** P< 0.001.
Time points Group M (n= 30) Group P (n= 30) P value
PACU
VAS 3 (0–5) 3 (0–6) 0.434
RSS 3 (1–5) 3 (1–4) 0.060
6 h
VAS 3 (1–5) 3 (0–5) 0.719
RSS 3 (1–3) 2 (1–3) 0.176
12 h
VAS 3 (0–6) 3 (0–5) 0.823
RSS 2 (1–3) 2 (1–2) 0.651
24 h
VAS 2.5 (0–4) 3 (0–4) 0.925
RSS 1 (1–3) 1 (1–2) 0.124
Group M=mirtazapine group; Group P = placebo group;
n= number; h = hours; PACU= post-anaesthesia care unit;
VAS = visual analogue scale; RSS = Ramsay sedation score.
Data are expressed median (range).group M (n= 30) and group P (n= 30). No patient was ex-
cluded from the study.
The two groups were comparable with regard to the demo-
graphic data (age, gender, and weight) and durations of sur-
gery and anesthesia (Table 1). Also, the two groups were
comparable with regard to the recovery time and PACU stay
(Table 2). Preoperative anxiety level measured by VAS was sig-
niﬁcantly lower in mirtazapine group (group M) compared to
placebo (group P) [3(1–5) vs. 8(5–9), respectively, P> 0.001]
(Table 2). Moreover, the propofol doses required to achieve
loss of RVC, loss ELR, and a target BIS45 were signiﬁcantly
lower in mirtazapine group (group M) compared to placebo
(group P), and the time needed for propofol achieving a target
BIS45 at a ﬁxed infusion rate of 50 mg min
1 in all patients in
both groups was signiﬁcantly shorter in mirtazapine group
(group M) in comparison to placebo group (group P) being
2.1 ± 0.26 vs. 2.5 ± 0.30 min, respectively, with estimated P
value >0.001 (Table 2).
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thesia and at a target BIS45 were comparable between both
groups (Table 3).
The two groups were comparable with regard to postoper-
ative pain (measured by VAS) and anxiety (measured by Ram-
say sedation score) recorded in the PACU (Table 4).4. Discussion
The main ﬁnding in the current study is that orally adminis-
tered mirtazapine 2 h before induction of anesthesia is effective
in reducing the preoperative anxiety level and induction dosing
of propofol without prolonging recovery or PACU stay times.
A previous study had investigated the effect of a single oral
dose mirtazapine (30 mg) on sleep demonstrated that mirtaza-
pine has a sleep-promoting effect when given 2 h before bed-
time [11]. Some preliminary studies of mirtazapine in anxiety
disorders have been published. One previous study [12] com-
pared the effect of diazepam 10 mg and mirtazapine 5, 15, or
30 mg with placebo on preoperative anxiety in female patients
undergoing gynecological surgery on the following day. Both
diazepam and mirtazapine reduced insomnia and preoperative
anxiety more than placebo. The anxiolytic and sleep-promoting
effects of mirtazapine are likely to be mediated via blocking
central 5-HT2 receptors. These ﬁndings are consistent with
the results of the current study as patients in mirtazapine group
exhibited signiﬁcantly less preoperative anxiety in comparison
to who received placebo. Mirtazapine is rapidly absorbed after
oral administration, and the peak plasma concentration is
reached within about 1.65 ± 0.7 h for fasting patients versus
2.4 ± 1.2 h for fed patients with elimination half-life of 20–
40 h [13]. The onset time of 5-HT2 receptors blocking effect
of mirtazapine matches its peak plasma concentration after
oral administration. The patients in the current study were fast-
ing before oral administration of mirtazapine and this explains
the fast onset of anxiolysis. Despite of long half-life of mirtaza-
pine, it did not prolong recovery time in the current study.
These results are consistent with a previous study conducted
by Chen et al. [14] on 80 female patients who had undergone
laparoscopic gynecologic procedures, and demonstrated that
a single oral dose of 30 mg of mirtazapine received 1 h before
surgery reduced preoperative anxiety level and promoted sleep
in 45% of patients without prolonging recovery time.
In October 1996, bispectral index (BIS) achieved approval
by the Food and Drug Administration as the ﬁrst electroen-
cephalogram (EEG)-based monitor of hypnotic component
of anesthetic state. BIS reduces complex EEG processing to
a simple number ranging from 100 (awake) to 0 (isoelectric
EEG), and decreasing values indicate more sedation and hyp-
nosis. BIS ranging from 40 to 60 correctly predicts absence of
consciousness [15]. Published data had demonstrated that BIS
correlates well with the level of responsiveness and accurately
predicts loss of consciousness with propofol [16–18], midazo-
lam [17,19], alfentanil, and isoﬂurane [17]. It had also been
demonstrated that the correlation of BIS to the level of seda-
tion is equal to, or even better than, using measured drug con-
centration [17]. Moreover, Gan and colleagues [20], in their
multicentric study conducted on three hundred two patients
at four institutions who received a propofol–alfentanil–nitrous
oxide anesthetic, concluded that titrating propofol with BIS
monitoring during balanced anesthesia reduced propofol usewith faster emergence and signiﬁcantly improved recovery.
Based on these previous data, BIS monitor was used in the cur-
rent study to evaluate adequate hypnosis induced by i.v propo-
fol infusion. A BIS value of 45 (BIS45) was determined in the
current study as a target value for adequate hypnosis with
no recall based on previous published data correlating the
BIS values with the level of sedation and hypnosis by various
sedatives and anesthetics. Glass et al. [17] in their multicentric
study evaluating the relation between BIS and increasing level
of sedation for propofol, midazolam, isoﬂurane, and alfentanil
concluded that BIS levels less than 50 indicate adequate hyp-
nosis with no recall. Furthermore, Lallemand et al. [21] in their
prospective, double blind study to test three currently used
induction doses of etomidate against both BIS values and clin-
ical criteria for adequate depth of general anesthesia have con-
cluded that a BIS value of 50 or less was associated with
absence of purposeful movements during orotracheal intuba-
tion and the absence of recall following administration of
etomidate.
Varying the rate of infusion induction of anesthesia with
propofol in healthy adults does not result in major differences
in changes in arterial pressure. However, induction by slow
infusion can be recommended because of the reduced dose
requirements, the lower incidence of apnea, and good patient
acceptance [22]. At induction of anaesthesia with propofol,
administration rates of approximately 50 mg min1 seem likely
to provide improved titration to effect without excessively pro-
longing induction and therefore, this rate of propofol infusion
during induction of anesthesia is suggested to be close to the
optimal rate in humans [23]. Consequently, in the current
study, at induction of anesthesia propofol infusion was ﬁxed
at a rate of 300 ml h1 (50 mg min1) in all patients.
In the current study, it was found that mirtazapine admin-
istered orally in a dose of 30 mg 2 h before surgery was effec-
tive in reducing propofol dose requirements to produce loss of
RVC, loss of ELR, and to achieve a target BIS value of 45 and
shortened the propofol induction time needed to achieve target
BIS value of 45. Also, there were not statistically or clinically
signiﬁcant reductions in arterial blood pressure in all studied
patients. The synergistic effect of mirtazapine can be explained
by its blocking effect to central 5-HT2 receptors enhancing
anxiolysis and promoting sleep. The onset time of 5-HT2
receptors blockade was matching the peak plasma concentra-
tion of mirtazapine after oral administration in fasting patients
which was synchronous with the time of propofol induction of
anesthesia providing synergistic effect to propofol with ulti-
mate effect of reducing propofol dose requirements. Conﬂict-
ing with our results, Chen et al. [14] in their study found
that a single oral dose of 30 mg of mirtazapine 1 h prior to sur-
gery did not reduce induction dose of propofol, however, in
mirtazapine group, the auditory evoked potential index at loss
of consciousness during induction was signiﬁcantly less than in
placebo group. The lack of reduction of propofol dosing can
be explained by the earlier time of propofol induction in Chen
et al. study which was not synchronous with the peak plasma
concentration of mirtazapine with insufﬁcient synergistic effect
of mirtazapine to propofol.
In conclusion, a single oral dose of mirtazapine 30 mg
administered 2 h before induction of anesthesia signiﬁcantly
reduces preoperative anxiety level and propofol induction dose
requirements at different stages of hypnosis with shorter induc-
tion time and without prolonging recovery time, and therefore,
Mirtazapine premedication: Effect on preoperative anxiety and propofol dose requirements 147it can be used as a premedication due to its anxiolytic and
sleep–promoting effects.
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